Security key
03237H101
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX)
CUSIP: 03237H101
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 112,323,168
- Total 13F value
- $1,356,917,552
- Share change
- +2,426,276
- Put/Call ratio
- 18%
- SEC-reported price per share
- $12.08
- Number of holders
- 181
- Value change
- +$21,178,269
- Number of buys
- 108
- Number of sells
- 71
- Shares outstanding
- 110,465,093
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
181
Top holders
10
AMLX full security history
Ownership snapshot
Full 13F holder table
Amylyx Pharmaceuticals, Inc. SEC filings
Amylyx Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
BlackRock, Inc.
7.1%
TCG Crossover GP II, LLC
5.7%
Commodore Capital LP
5.1%
Point72 Asset Management, L.P.
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$198,938,502
16,468,419 shares
|
+$61,477,681 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.1%
from 13D/G
|
$97,042,005
7,140,692 shares
|
— | 30 Sep 2025 |
| TCG Crossover GP II, LLC |
13D/G
|
5.7%
|
$74,863,306
6,243,812 shares
|
$0 | 31 Dec 2025 |
| Commodore Capital LP |
13D/G
13F
Company
|
5.1%
|
$89,213,500
5,650,000 shares
|
$0 | 10 Nov 2025 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
2.6%
|
$38,074,233
2,801,636 shares
|
-$26,039,432 | 30 Sep 2025 |
| Panacea Innovation Ltd |
13D/G
Panacea Venture Healthcare Fund II, L.P.
|
2.6%
|
$11,792,000
2,200,000 shares
|
$0 | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
181
Shares
112,323,168
Rows available
181
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
168
Q4 2025 holders
181
Holder diff
13
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|